Email this article Clinical case use bevacizumab for patient with metastatic ovarian cancer
- Authors: Oganyan M.R.1, Davidenko O.V.1
-
Affiliations:
- Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar
- Issue: No 2 (2014)
- Pages: 68-72
- Section: GYNECOLOGY. TREATMENT
- Published: 18.07.2014
- URL: https://ojrs.abvpress.ru/ojrs/article/view/31
- DOI: https://doi.org/10.17650/1994-4098-2014-0-2-68-72
- ID: 31
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
High incidence and mortality rate for ovarian cancer patients, short-term survival until relapse, repeated following surgeries and chemo- therapy, and also low survival rates make the problem of treatment of this pathology vital. Nowadays combination of platinum and paclitaxel (gemcitabine) in addition with targeted therapy (bevacizumab) is the most effective chemotherapy for first and second line of stages III and IV ovarians cancer. Considering high efficacy of these combinations aimed at the improving of the results of survival, further study of the use of bevacizumab in metastatic ovarian cancer therapy is necessary.
М.Р. Оганян, О.В. Давиденко
ГБУЗ «Клинический онкологический диспансер No 1» Минздрава Краснодарского края, Краснодар Контакты: Мариэтта Рафаэловна Оганян kapurol@mail.ru
Keywords
About the authors
M. R. Oganyan
Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar
Author for correspondence.
Email: kapurol@mail.ru
Russian Federation
O. V. Davidenko
Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, KrasnodarRussian Federation
References
Supplementary files
